Literature DB >> 31339679

Shingrix for Herpes Zoster: A Review

Radhika A Shah1, Allison L Limmer2, Crystal E Nwannunu2, Ravi R Patel3, Uyen Ngoc Mui3, Stephen K Tyring2,3.   

Abstract

Herpes zoster (HZ), also known as shingles, results from reactivation of the latent varicella-zoster virus (VZV), which commonly causes chickenpox in childhood. Greater than 90% of adults are infected with this virus, putting them at risk for reactivation. HZ presents as a painful, vesicular rash distributed in a unilateral and dermatomal pattern along dorsal root or cranial nerve ganglia. The rash often presents with prodromal symptoms and progresses to include clear vesicular clusters, evolving through stages of pustulation, ulceration, and crusting. HZ therapy currently involves the use of antiviral agents and pain management; however, HZ prophylaxis has been strongly recommended in older adults through vaccination with a live attenuated vaccine, Zostavax®. A new recombinant subunit vaccine, HZ/su (Shingrix®), is the subject of this review. In clinical trials, HZ/su demonstrated an overall vaccine efficacy of 97.2% among participants 50 years of age or older, indicating a significantly reduced risk of HZ in these individuals. Shingrix® was approved by the US FDA in October 2017 as HZ prophylaxis. Skin Therapy Letter © (ISSN 1201–5989) Copyright 2019 by SkinCareGuide.com Ltd. Skin Therapy Letter © is published 6 times annually by SkinCareGuide.com Ltd, 1003 - 1166 Alberni Street, Vancouver, British Columbia, Canada, V6E 3Z3. All rights reserved. Reproduction in whole or in part by any process is strictly forbidden without prior consent of the publisher in writing. While every effort is made to see that no inaccurate or misleading data, opinion, or statement appears in the Skin Therapy Letter ©, the Publishers and Editorial Board wish to make it clear that the data and opinions appearing in the articles herein are the responsibility of the contributor. Accordingly, the Publishers, the Editorial Committee and their respective employees, officers, and agents accept no liability whatsoever for the consequences of any such inaccurate or misleading data, opinion, or statement. While every effort is made to ensure that drug doses and other quantities are presented accurately, readers are advised that new methods and techniques involving drug usage, and described herein, should only be followed in conjunction with the drug manufacturer’s own published literature.

Entities:  

Keywords:  herpes zoster; rash; recombinant subunit vaccine; shingles; Shingrix; treatment; vaccine; varicella zoster virus

Year:  2019        PMID: 31339679

Source DB:  PubMed          Journal:  Skin Therapy Lett        ISSN: 1201-5989


  7 in total

1.  Physical Characteristics of Injection Site Pain After COVID-19 mRNA BNT162b2 Vaccination.

Authors:  Katsuyuki Tomita; Shinichi Okada; Shuji Sugihara; Tomoyuki Ikeuchi; Hirokazu Touge; Junichi Hasegawa; Akira Yamasaki
Journal:  Yonago Acta Med       Date:  2021-11-10       Impact factor: 1.641

2.  The incidence rate of herpes zoster in inflammatory bowel disease: A meta-analysis of cohort studies.

Authors:  Shih-Wei Lai; Kuan-Fu Liao; Cheng-Li Lin; Yu-Hung Kuo; Chiu-Shong Liu; Bing-Fang Hwang
Journal:  Medicine (Baltimore)       Date:  2021-08-20       Impact factor: 1.817

Review 3.  Advancements in protein nanoparticle vaccine platforms to combat infectious disease.

Authors:  Nina Butkovich; Enya Li; Aaron Ramirez; Amanda M Burkhardt; Szu-Wen Wang
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2020-11-08

Review 4.  Aging and Options to Halt Declining Immunity to Virus Infections.

Authors:  Miguel Ángel Palacios-Pedrero; Albert D M E Osterhaus; Tanja Becker; Husni Elbahesh; Guus F Rimmelzwaan; Giulietta Saletti
Journal:  Front Immunol       Date:  2021-05-12       Impact factor: 7.561

Review 5.  40 Years after the Registration of Acyclovir: Do We Need New Anti-Herpetic Drugs?

Authors:  Anna Majewska; Beata Mlynarczyk-Bonikowska
Journal:  Int J Mol Sci       Date:  2022-03-22       Impact factor: 5.923

6.  Mucosal Vaccination With Recombinant Tm-WAP49 Protein Induces Protective Humoral and Cellular Immunity Against Experimental Trichuriasis in AKR Mice.

Authors:  Junfei Wei; Venkatesh L Hegde; Ananta V Yanamandra; Madison P O'Hara; Brian Keegan; Kathryn M Jones; Ulrich Strych; Maria Elena Bottazzi; Bin Zhan; K Jagannadha Sastry; Peter J Hotez
Journal:  Front Immunol       Date:  2022-02-07       Impact factor: 7.561

7.  Promotion of Cellular and Humoral Immunity against Foot-and-Mouth Disease Virus by Immunization with Virus-Like Particles Encapsulated in Monophosphoryl Lipid A and Liposomes.

Authors:  Woo Sik Kim; Yong Zhi; Huichen Guo; Eui-Baek Byun; Jae Hyang Lim; Ho Seong Seo
Journal:  Vaccines (Basel)       Date:  2020-10-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.